Download - VIP-HESI dual source
Innovation with IntegrityQTOF and t imsTOF MS
Next generation in Mass Spectrometry sensitivity
Bru
ker
Dal
toni
cs is
con
tinua
lly im
prov
ing
its p
rodu
cts
and
rese
rves
the
rig
ht
to c
hang
e sp
ecifi
catio
ns w
ithou
t no
tice.
© B
DA
L 0
6-2
021,
18
89
04
6, R
ev. 0
1
VIP-HESI dual source
Vacuum Insulated Probe – Heated Electrospray Ionisation (VIP-HESI) has been migrated from the proven EVOQ Elite and coupled to Bruker QTOF and timsTOF systems. Together they deliver
All these enhancements bring ‘triple quad like’ performance into the realms of accurate mass in mass spectrometry allowing the analyst to benefit from
• Highest performing accurate mass system
• Greatest sensitivity with no thermal breakdown of molecules
• Robustness to analyse a multitude of samples provided by the ‘Active Exhaust’
• Sensitivity enhancements across all flow rate regimes – 5 to 15 fold
• Positive and negative ion acquisition modes
• Higher sensitivity with complex matrices
• Increased sensitivity across all mobile phase compositions
• Enhanced APCI performance
• Increased confidence in compound identification due to many confirmatory ions
- Reduced false positive and false negative reporting
- Further enhanced by collisional cross section values with Trapped Ion Mobility Spectrometry systems (TIMS)
• Retrospective analysis as system collects "all the data all of the time"
- Removes the requirement to store samples and re-inject, just reprocess the data
• Unlimited number of compounds analysed per run
- Sensitivity remains constant even when screening for many hundreds of compounds
• Up to 5 orders of linear dynamic range• Highly reproducible data with low RSD
values
VIP-HESI dual source Next generation in Mass Spectrometry sensitivity
High-efficiency ceramic heater technology, with configured thermal profiling, delivers highest heat near the probe tip.
Shape vacuum insulation protects the LC eluent from boiling before nebulization.
Fluid path remains cool before nebulization, which is essential for protecting thermally fragile compounds.
Drugs of Abuse in HairCocaine in hair analysis. The analysis below was 0.3 pg/ml
Drug Mixtures in UrineAverage intensity gain of 5.1 for drug mixtures in urine
What would this bring to your lab?• Less hair sample needed, less
disruption• More accurate hair “time line” of drugs
of abuse usage• Comparable examples on LC-MS/MS
indicate same sensitivity level• Full screening and quantification for
large libraries• Identification possibilities for NPS drugs
Average improvement drugs of abuse in hair: 16.1 fold
What would this bring to your lab?• Lower detection limits, comparable
with LC-MS/MS on triple quadrupole instruments
• Signal to noise improvement by high resolution to achieve sensitivity in matrix
• Higher sensitivity often allows smaller injection volumes which can improve robustness
• Low quantification with full screening possibilities
• Easy addition of new targets into the screening method
Average improvement drugs in urine sample: 5.1 fold
2
x103 B 1_100_14_1010Cocaine - C17H21NO4 - +
B 1_100HESI_13_1_5198 Cocaine - C17H21NO4 - +
x103
8.0 8.0
7.0 7.0
6.0 6.0
5.0 5.0
4.0 4.0
3.0 3.0
2.0 2.0
1.0 1.0
4.3 4.34.5 4.54.7 4.7Time [min] Time [min]In
ten
sity
Inte
nsi
ty
Current VIP-HESI
Current
3.252.752.52.250
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
1 ppb Apollo-16054-Acetamidoantipyrine(4-AAA) - C12H
15N2O2 -+++
246 - M+nH(*) (PI) (q)
2.92
,4-A
ceta
mid
oant
ipyr
ine
(4-A
AA
)
4.5
5.0
3 Time [min]
x103
Inte
nsi
ty
VIP-HESI
3.252.752.52.250
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
3 Time [min]
x103
Inte
nsi
ty
QqQ
2.30
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
x103
2.4 2.5 2.6 2.7 2.8 Time [min]
Inte
nsi
ty
1 ppb Apollo-14234-Acetamidoantipyrine(4-AAA) - C12H
15N2O2 -+++
246 - M+nH(*) (PI) (q)
2.95
,4-A
ceta
mid
oant
ipyr
ine
(4-A
AA
)
1 ppb Apollo4-ACETMIDO ANTIPYRENE -+++
(+)246.2 > 104.0 [38.0V](*)(PI)(q)(+)246.0 > 83.0 [51.0V](*)
2.75
2.74
, 4-A
CET
MID
O A
NTI
PY
RE
NE
2.74
Lipids in plasmaAverage gain of 4.9 for lipids in plasma
Pesticides in Water Pesticide analysis in water. Commercial lab test on certified QqQ levels with VIP-HESI
What would this bring to your lab?• Increased screening possibilities
without limitation in the number of analytes monitored
• No need to re-run screening on second LC-MS/MS system for quantitation
• Retrospective screening at triple quadrupole LC-MS/MS level, looking back to newfound compounds without re-injecting samples
• Full screening and quantification for large libraries
• Looking for suspects, identifying unknowns by using the same VIP-HESI (tims or Q)TOF solution
• Retrospective trend reporting for new environmental risk components
What would this bring to your lab?• Improve the number of unique lipid
annotations using a VIP-HESI source• Increase the LOD of your lipid targets • Get an extended dynamic range for lipid
quantitation• Reduce false positives by improving the
quality of MS/MS spectra• Further increase confidence in
annotation using CCS-enabled 4D-Lipidomics
Average improvement lipids in plasma: 4.9 fold
105104
104
105
103x105
x105
1 2 3 4 5
1031
2
3
4
5
6
00
log Quantity expected [ppt]Quantity expected [ppt]
Inte
nsi
ty
Inte
nsi
ty
VIP-HESIVIP-HESI CurrentCurrent
Average improvement pesticides in environmental water sample: 8.1 fold
5.45.25.04.8
CurrentVIP-HESI
4.64.44.2 5.6
Overlay of VIP-HESI and current ion source
Forensic Toxicology Mix Analysis with VIP-HESI APCI
Analysis of PFAS using VIP-HESI and Ion MobilityPFAS analysis moves to the next level with VIP-HESI, QTOF and optional Ion Mobility
What would this bring to your lab?• Benefit from the specificity of LC-APCI
by switching from VIP-HESI mode in minutes
• Benefit from the enhanced sensitivity typically experienced with neutral or more lipophilic compounds
What would this bring to your lab?• Screen many of the PFAS components at enhanced
sensitivity with isomeric separation via TIMS• Ion mobility can increase S/N ratio especially in
complex matrix• Easily adapt to changing regulations on PFAS with VIP-
HESI (tims or Q)TOF hardware in the future
Average improvement of PFAS standard in water: 9.8 fold
Average improvement of LC-APCI analyzed drugs: 18.1 fold
Current
x104
x105
VIP-HESI
2
2
4
6
8
4
6
8
00 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
0
Time [min]
2
2
4
6
x105
4
6
04 5 6 6 8 9 10
Current
VIP-HESI
0 08 89 910 1011 11
200 100
200
300
400
400
600
800
1000
Time [min] Time [min]
tims Ontims Off
PFAS 1 pbb_MultiCE_4_3513.d
PFB
AP
FBA
L-P
FBS
L-P
FBS
PFO
A
PFO
PA
PFO
A
L-P
FOS
L-P
FOS
FOE
A
8:2F
TS8:
2FTS
BC
IPFO
SB
CIP
FOS
Bru
ker
Dal
toni
cs is
con
tinua
lly im
prov
ing
its p
rodu
cts
and
rese
rves
the
rig
ht
to c
hang
e sp
ecifi
catio
ns w
ithou
t no
tice.
© B
DA
L 0
6-2
021,
18
89
04
6, R
ev. 0
1
Bruker Daltonics GmbH & Co. KG
Bremen · GermanyPhone +49 (0)421-2205-0
Bruker Scientific LLC
Billerica, MA · USA Phone +1 (978) 663-3660
[email protected] - www.bruker.com
For Research Use Only. Not for use in clinical diagnostic procedures.
• Reduced sample preparation saving time and money?• Detecting lower levels of drugs and metabolites for deeper understanding?• Finding new emerging contaminants sooner?• Simpler method development, again saving time?• Seamless transition between targeted and untargeted workflows on the same instrument?
• Increase the sensitivity of components drastically without additional cost of a second source
• More flexibility in ionisation techniques without changing ion sources
Utilize ion mobility separation to run faster chromatographic gradients and reduce noise even further resulting in improved S/N values.
High Resolution Mass Spectrometry opening new possibilities with Ion Mobility and VIP-HESI dual source
VIP-HESI dual source, TASQ and Metaboscape® - easy to use, robust, most sensitive high resolution LC-MS solution
VIP-HESI dual source What would a 5-fold increase in accurate mass in mass spec-trometry sensitivity bring to your lab for almost any application?
What would a real ESI/APCI dual source bring to your lab?
